ReviewESMO real world data and digital oncology2026
AI assistance in tumor multidisciplinary teams.
Review in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidisciplinary teams (MDTs), the cornerstone of modern cancer care, are facing significant operational inefficiencies. These challenges include the laborious, manual synthesis of unstructured, multimodal patient data for case preparation, which is time-consuming and prone to information overload. Furthermore, heterogeneous operational processes across MDTs themselves compound these issues. Additionally, clinical decisions are often archived in static documents, preventing the systematic collection of decision rationales essential for continuous learning and research. We propose that artificial intelligence (AI), particularly natural language processing (NLP) and large language models (LLMs), can act as integrated partners to solve these problems. The capacity of AI to seamlessly integrate diverse datasets-including imaging, histopathology, genomics, and clinical data-may be instrumental in enhancing diagnostic accuracy, refining personalized treatment plans within a complex cancer management journey. This integration can be achieved through a tiered approach, utilizing models from small NLP for targeted information extraction to foundational generative NLP for complex evidence synthesis, while addressing key challenges in validation, ethical governance, and regulatory oversight. International initiatives are actively developing validated frameworks to facilitate the widespread and standardized adoption of these AI solutions, while taking into account heterogeneous operational processes. By improving data management, streamlining decision making, and establishing crucial feedback loops, AI integration promises to enhance patient outcomes and optimize resource utilization within cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.